Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Findings from a recent study suggest large language models (LLMs) like ChatGPT and Gemini are not sufficient tools for providing dietary recommendations for patients with 

While ChatGPT provided mostly compliant responses with current dietary guidelines for IBS, study results emphasize the need for further model improvements before relying solely on LLMs in clinical nutrition practice, highlighting the importance of dietitians' recommendations and the collaboration between AI models and healthcare teams.

Despite recent advancements in public awareness and treatment options, findings from the American Gastroenterological Association’s 2025 IBS in America survey shed light on persistent challenges faced by patients with IBS as well as shifts in patient experiences, health care provider perceptions, and the treatment landscape. Artificial intelligence tools have shown promise for other healthcare-related uses like antimicrobial stewardship in hospital settings, but their utility for IBS remains underexplored.

“While some studies show that the nutrition and health advice provided by LLMs are similar to that of healthcare professionals, others show that they provide inaccurate and nonevidence-based advice,” Merve Kip, a research assistant in the department of nutrition and dietetics at Nuh Naci Yazgan University in Turkey, and colleagues wrote.

 “To our knowledge, there are no studies evaluating the dietary recommendations for IBS given by LLMs.”

To address this gap in research, investigators conducted a cross-sectional comparative study assessing nutrition recommendations for IBS generated by ChatGPT-4o mini and Gemini 1.5 regarding guideline compliance, quality, understandability, actionability, and readability. They additionally assessed the correlation between quality, guideline compliance, and patient education tool scores of LLMs.

Investigators created a set of 10 frequently asked questions based on the most frequently cited and commonly used guidelines as well as on their clinical experience regarding commonly raised concerns by IBS patients. These questions represented typical patient issues, including which diet to follow for IBS, foods that have a positive/negative effect, the consumption of coffee and tea, ingredients to avoid in packaged foods, allowable fruit intake, appropriate supplements, and what to eat or avoid in cases of constipation, diarrhea, or bloating.

The free versions of LLMs were used in the study because they were deemed to be the most accessible to patients. Before starting the study, investigators cleared the browser history and all chat history. A new chat window was then opened for each question to avoid any possible context transfer, and each question was asked 4 times every 15 minutes.

The Guideline Compliance Score was created by researchers, using the most frequently cited and commonly used IBS guidelines. Additionally, they used the Global Quality Score (GQS) and Completeness, Lack of Misinformation, Evidence, Appropriateness, Relevance (CLEAR) tool to analyze the quality of the responses given by the LLMs. All responses were evaluated for their understandability and actionability scores using the Patient Education Materials Assessment Tool (PEMAT), and ease of reading was assessed using Flesch Kincaid Grade Level (FKGL) and Flesch Reading Ease (FRE).

Results showed most answers given by ChatGPT (70%) and Gemini (57.5%) were compliant with the guidelines. ChatGPT provided “compliant” (70%) or “partially compliant” (30%) responses, while Gemini provided “compliant” (57.5%), “partially compliant” (20%), and “Noncompliant” (22.5%) responses to the questions.

Further analysis revealed ChatGPT had higher mean scores than Gemini for GQS, Guideline Compliance, and PEMAT understandability and actionability scores, but without statistical significance (

 > .05). Of all assessed measures, Gemini scored significantly higher than ChatGPT only in the Evidence subscore (

Investigators noted the mean FRE score of Gemini was higher (49.68 ± 4.82) than ChatGPT (46.06 ± 4.52), which corresponded to “difficult to read” for both LLMs (

 >.05). Additionally, both ChatGPT and Gemini were classified as ‘very good content’ based on their CLEAR scores (19.29 ± 1.59 and 19.59 ± 4.72, respectively).

GQS and CLEAR, showed a strong positive correlation (

 = .004). The CLEAR score showed a moderate positive correlation with both PEMAT actionability (

 = .009). Readability scores, FRE and FKGL, had a strong negative correlation (

 <.001), while the Guideline Compliance Score showed a moderate negative correlation with FRE (

“Our study suggests that patients should be aware of the risk of relying on LLMs alone in practice, as they may provide inaccurate or incomplete information,” investigators concluded.

 “This study highlights the further need for model improvements or the development of new LLMs before their use in clinical nutrition practice. With future model refinement and development, AI technology can be used as an assistant tool that is always available to patients rather than replacing the advice of dietitians.”

Kip M, Bozan GS, Sahin GA. Large Language Models for Dietary Advice to Patients With Irritable Bowel Syndrome: ChatGPT vs. Google Gemini. 

. 2025;38(6):e70162. doi:10.1111/jhn.70162

Brooks A. Despite Advances, IBS Continues to Impact Patients' Daily Lives, Productivity. HCPLive

August 8, 2025. Accessed November 24, 2025. 

https://www.hcplive.com/view/despite-advances-ibs-continues-to-impact-patients-daily-lives-productivity

Brooks A. AI Tool Shows Promise for Antimicrobial Stewardship, C Diff Prevention in Hospitals. HCPLive. June 13, 2025. Accessed November 24, 2025. 

https://www.hcplive.com/view/ai-tool-shows-promise-antimicrobial-stewardship-c-diff-prevention-hospitals

Articles

Recent research indicates that large language models (LLMs) like ChatGPT and Gemini are not yet reliable for providing dietary recommendations for IBS patients. While ChatGPT showed higher guideline compliance than Gemini, both models require further refinement before being used in clinical nutrition practice. The study highlights the importance of dietitians' expertise and collaboration with AI tools. Despite some promise in other healthcare applications, LLMs' utility for IBS remains limited. The study underscores the need for model improvements to ensure accurate and evidence-based dietary advice for IBS patients.

Study findings suggest ChatGPT and Gemini both require further model improvements before relying solely on LLMs in clinical nutrition practice.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode of Diabetes Dialogue, hosts discuss Semaglutide for Alzheimer Disease and new trial data on Tirzepatide showing promise in T1D

Diabetes Dialogue: Semaglutide Falls Short Alzheimer Disease, Tirzepatide Shows Promise in T1D

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, breakdown recent trial news from the 2 most popular incretin therapies: semaglutide and tirzepatide. First, hosts breakdown the November 24, 2025 announcement from Novo Nordisk disclosing their evoke and evoke+ trials of oral semaglutide in early symptomatic 

 failed to slow disease progression. Next, hosts break down the TIRTLE study, which examined use of tirzepatide in patients with 

Semaglutide Misses Mark in Alzheimer Disease

Novo Nordisk announced top-line results from the evoke and evoke+ phase 3 trials showing oral semaglutide 14 mg did 

 slow disease progression over 2 years in adults with early symptomatic Alzheimerdisease, with no significant difference in CDR-SB change versus placebo. Despite improvements in Alzheimer-related biomarkers across both studies, neither trial demonstrated a slowing of clinical decline.

evoke was a global, randomized, double-blind, placebo-controlled trial enrolling 1,855 participants aged 55–85 with amyloid-positive CDR 0.5 MCI or CDR 1.0 mild dementia, treated 1:1 with semaglutide or placebo for 104 weeks plus a planned 52-week extension. evoke+ mirrored this design, randomizing 1,953 participants with the same eligibility criteria to daily semaglutide 14 mg or placebo for a total planned duration of 156 weeks.

Findings from the trials will be presented at the 2025 Clinical Trials in Alzheimer’s Disease (CTAD) conference on December 3, 2025. The lack of efficacy led to discontinuation of the planned 1-year extension period across both trials, though safety and tolerability remained consistent with prior semaglutide experience in diabetes and obesity.

TIRTLE: Tirzepatide Shows Benefit in Type 1 Diabetes

In a 12-week, double-blind, placebo-controlled phase 2 trial of 24 adults with type 1 diabetes and BMI >30 kg/m², tirzepatide produced a 10.3-kg mean weight loss versus 0.7 kg on placebo, an −8.7-kg treatment difference (

 < 0.0001) corresponding to 8.8% total body weight reduction.

All tirzepatide-treated participants achieved ≥5% weight loss, and 45% achieved ≥10%, compared with 9% and 0% in the placebo group. Eligibility criteria required patients to be 18 years of age or older, with confirmed type 1 diabetes, obesity (BMI >30), and stable insulin therapy. Tirzepatide also improved glycemic control, reducing HbA1c by 0.4%, and decreased total daily insulin dose by 35% relative to placebo (−24.2 vs −0.3 units/day). Safety data suggested no significant adverse events occurred, with 22 of the 24 participants completing the study.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Novo Nordisk. Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression. Novo Nordisk. November 24, 2025. Accessed November 24, 2025. 

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462

Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. 

. Published online November 20, 2025. doi:

Podcasts

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D

Shannon C. Trotter, DO, is a dermatologist and podcast host from Springfield, Ohio.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

2025 Society of Dermatology Physician Associates (SDPA) Fall Conference

 in San Antonio, Texas, featured a variety of interviews with experts in the field of dermatology.

One such interview featured Shannon C. Trotter, DO, a dermatologist and podcast host with DOCS Dermatology, who discussed the topics covered in several sessions she presented at SDPA. First, Trotter was asked about the biggest highlights from her talk regarding social media and its connection to dermatology.

“You've got to get used to it,” Trotter said. “You have got to be aware of it and consume it, just like your patients do. Social media is, in fact, the new Web MD. Actually, one out of five patients will go to check social media, in particular, TikTok, before they even consult their doctor. It's important for us to be aware of what's out there, so that we can combat any misinformation, and that we can be a force as clinicians to really educate the public on everything skin.”

Later in her interview, Trotter was asked to discuss some of the most notable takeaways from her session titled ‘Advanced Breakout - I'm Lichen It! Lichenoid Disorders in Dermatology.’

 Trotter spoke about lichenoid disorders and several tips worth highlighting for clinicians.

“In particular, lichen planus can affect anything from skin that you think of classic skin locations like the hair and the nails,” Trotter explained. “In addition, it can also have different variations for effects inside the ear, or even the esophagus or the bladder. So it's important to be aware that it's more than just your regular LP, or lichen planus. Next is the fact that we have to have good treatments. The problem is, for these lichenoid disorders, we just don't have a lot of treatments to offer, so we have to get creative and often go off-label. And lastly, be aware of lichenoid drug eruptions.”

Trotter also pointed to the cancer management space, noting immunotherapy and targeted therapy with immune checkpoint therapy are leading to lichenoid drug reactions. She urged clinicians to keep this in mind. Later, Trotter touched on the topic of granuloma annulare.

“Granuloma annulare is one of my favorite rashes in all of dermatology,” Trotter said. “But keep in mind, although it's benign and more common than you might think, it does have associations that you want to be aware of, including autoimmune disorders and some lymphoproliferative disorders, in particular, non-Hodgkin's and Hodgkin's lymphoma. It can be very challenging to treat as well, so you might have to get creative to help your patients get successful with treatment, and you might have to do more workup than you might expect.”

The quotes used in this video summary were edited for clarity.

Trotter disclosures include her work for Castle Biosciences as a consultant, researcher, and speaker.

Trotter S. Social Media Trends 2025. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Trotter S. Advanced Breakout - I'm Lichen It! Lichenoid Disorders in Dermatology. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Trotter S. The Ringmaster: Taming Granuloma Annulare. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Videos

This interview at the SDPA Fall Dermatology Conference highlights several topics covered in sessions presented by Trotter.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Matthew Dapas, PhD, research assistant professor at Northwestern University Feinberg School of Medicine

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

At the American College of Rheumatology (ACR) Convergence 2025 in Chicago, Matthew Dapas, PhD, research assistant professor at Northwestern University Feinberg School of Medicine, discussed how polygenic risk scores are helping to clarify the heterogeneity of systemic lupus erythematosus (SLE) and inform clinical understanding of disease manifestations.

Systemic lupus erythematosus (SLE) presents a wide range of clinical manifestations, complicating diagnosis. Mayo Clinic notes symptoms such as fatigue, fever, joint pain, a butterfly-shaped facial rash, sun-sensitive skin lesions, color changes in fingers and toes, shortness of breath, chest pain, dry eyes, headaches, confusion, and memory loss.

 Clinicians use classification criteria, like those from the Systemic Lupus International Collaborating Clinics (SLICC), to guide diagnosis and management.

“[Lupus is] a very heterogeneous disease,” Dapas told 

during ACR. “[Lupus in] one individual …might look pretty different from another individual that has lupus. So how do we engineer these diagnosis classification criteria to best fit this wide variety of manifestations that can come about from this one disease? With my work, we build these genetic risk models to…see to what extent these different diagnostic criteria or classification criteria [capture] different types of disease…We can use these genetic models and their associations as a tool to basically increase our ability to pinpoint the exact disease in an individual. It's part of this push towards personalized medicine.”

Using data from a genome-wide association study of 6,748 SLE cases and 11,516 controls of European ancestry, Dapas and colleagues developed a polygenic risk score that predicted SLE with an area under the curve of 0.724.

Within the Northwestern cohort (n = 1,061), the polygenic risk score showed strong associations with lupus diagnoses (“Lupus [localized and systemic],” P = 1.6×10⁻⁹; “systemic lupus erythematosus,” P = 3.0×10⁻⁹), and nominal associations with cardiac complications (P = 2.8×10⁻³) and impaired renal function (P = 4.6×10⁻³), suggesting genetic risk may drive distinct phenotypic patterns.

The team then analyzed the correlation between the polygenic risk score and individual SLICC classification criteria in > 32,000 eMERGE participants. The polygenic risk score was significantly associated with 5 of 6 immunologic criteria and 3 of 11 clinical criteria, including acute cutaneous lupus, thrombocytopenia, and leukopenia. The strongest association was with low complement levels (P = 7.4×10⁻³¹), where patients in the highest polygenic risk score decile were nearly twice as likely to have low complement as those in the lowest decile (55% vs. 30%).

These findings suggest that immunologic features more closely reflect underlying genetic risk, while some clinical manifestations may be influenced by environmental factors or represent phenotypes not captured in the original genome-wide association study.

“We want to get to a place where, if a clinician [is] seeing a new patient that they suspect may have an autoimmune disease like lupus, they can order a genetic panel in addition to the other labs that they might order to try and assess this patient. This could go for newly diagnosed lupus patients as well. If you have a genetic risk panel, that genetic risk could be specific to certain complications or classification, or just lupus itself. You can include particular HLA alleles that can essentially inform the physician with greater certainty what the individual risk profile is for that patient.

He said that a patient with a greater genetic risk score for lupus with certain HLA alleles may be at a greater risk for particular outcomes from lupus that may warrant more observation or the order of a specific test.

“Ultimately, we're trying to use genetics as an additional tool in the physician’s toolkit to better tailor their treatment to their individual patients and better understand the disease of the individual patients, because, like I said from the outset, conditions like lupus [are] very heterogeneous, and it's not a one-size-fits-all solution for everyone.”

Dapas has no relevant reported disclosures.

Forrest N, Tuteja S, Pacheco J, Mitrovic V, Ramsey-Goldman R, Walunas T, Dapas M. Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). 

https://acrabstracts.org/abstract/polygenic-risk-of-lupus-is-differentially-associated-with-individual-ehr-derived-classification-criteria/

Mayo clinic. Lupus - Symptoms and Causes. Mayo Clinic. Published October 21, 2022. 

https://www.mayoclinic.org/diseases-conditions/lupus/symptoms-causes/syc-20365789

Polygenic risk scores are enhancing the understanding of systemic lupus erythematosus (SLE) by clarifying its heterogeneity and informing clinical practice. SLE's diverse manifestations complicate diagnosis, but genetic models are helping to refine classification criteria. A study using genome-wide association data developed a polygenic risk score with significant predictive power for SLE and its complications. The score showed strong associations with immunologic criteria, suggesting genetic risk influences certain phenotypes. This approach supports personalized medicine, enabling clinicians to tailor treatments based on individual genetic risk profiles.

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Lupus

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 shows slow disease progression over 5 years, increased rates of complete kidney remission, and a common pattern of recurrence, supporting extended follow-up and improved predictive models.

The silent progression of IgAN in children stems from persistently active kidney injury, which can lead to irreversible sclerotic damage. A 20-year study of early-onset IgAN found about 20% of children experienced kidney function decline or reached a combined renal endpoint, including end-stage kidney disease, doubling of serum creatinine, or death.

The retrospective cohort study evaluated poor prognosis, estimated glomerular filtration rate (eGFR), and the patterns of kidney remission and relapse in children, aiming to identify reliable prognostic markers to guide clinical management.

“IgAN is one of the major causes of chronic kidney disease (CKD) and kidney failure among pediatric glomerulopathies, with marked heterogeneity in clinical course and prognosis,” wrote Liru Qiu, MD, PhD, department of pediatrics at Tongju Hospital, and colleagues. “We systematically analyzed baseline characteristics, clinicopathological features at biopsy, and follow-up data.”

The study included 224 patients 3-18 years of age with biopsy-proven IgAN and ≥ 3 years of follow-up. Poor prognosis was defined as persistent eGFR < 90 mL/min/1.73 m2 for ≥ 3 months, kidney failure, or a ≥ 30% reduction in eGFR from baseline. Complete kidney remission was defined as the absence of hematuria and proteinuria with eGFR ≥ 90 mL/min/1.73 m2 for ≥ 1 year, and recurrence.

During a 5.41 year median follow-up, investigators observed poor prognosis in 12.05% of patients. Notable independent risk factors were found in males, older age at biopsy, Oxford classification E1 and S1 lesions, absence of gross hematuria, and no remission of proteinuria during follow-up, whereas those with elevated birth weight had reduced risk of adverse outcome (

Investigators also noted an association between age at biopsy, gross hematuria, and proteinuria remission status had significant time-dependent effects on eGFR slope. Patients < 12 years of age at biopsy demonstrated a decreased rate of kidney function decline compared to an increased eGFR rate for those ≥12 years of age, suggesting age of diagnosis might affect progression. When compared with isolated gross hematuria and no gross hematuria, patients with recurrent gross hematuria had an increased eGFR slope. Those with complete remission of proteinuria had a slower decline in kidney function than the non-remission group, suggesting a protective effect.

Investigators observed complete kidney remission in 70.98% of patients. The cumulative incidence of complete kidney remission at 2, 5, and 10 years post-biopsy was 23.21% (95% confidence interval [CI],17.67-28.76), 64.33% (95% CI, 57.58-71.08), and 84.03% (95% CI, 76.64-91.43), respectively. Among those in remission, 39.62% (63/159) remained relapse-free, while 60.38% (96/159) relapsed, including hematuria (29.17%), proteinuria (38.54%), or both (32.29%), underscoring the particularly elastic and variable nature of disease progression in pediatric patients with IgAN.

“Future research should leverage multicenter cohorts and integrate multi-omics approaches—including genomic, metabolic, and inflammatory profiling—to enhance prognostic accuracy and guide precision therapy in pediatric IgAN,” concluded investigators.

Liang W, He Y, Ma X, et al. Prognosis and predictive factors in pediatric IgA nephropathy. 

. Published online November 13, 2025. doi:

https://doi.org/10.1007/s00467-025-06988-8

Peruzzi L, Coppo R. IgAN Across the Age Spectrum: The Pediatric Perspective. 

. Published online March 2025:151569. doi:

https://doi.org/10.1016/j.semnephrol.2025.151569

Pediatric IgA nephropathy (IgAN) exhibits slow progression over five years, with increased complete kidney remission rates and common recurrence patterns, necessitating extended follow-up and improved predictive models. A 20-year study revealed that 20% of children with early-onset IgAN experienced kidney function decline or reached severe renal endpoints. A retrospective cohort study identified prognostic markers, highlighting risk factors such as male gender, older age at biopsy, and specific pathological lesions. Complete kidney remission was observed in 70.98% of patients, with a significant portion experiencing relapse, emphasizing the disease's variable progression.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

Evan Stein, MD, PhD, is the COO and CSO of LIB Therapeutics.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Lerodalcibep Efficaciously Reduces LDL-C Lastingly and Long-Term, With Evan Stein, MD, PhD

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Socioeconomic, Environmental Disadvantage Linked to Pediatric MASLD Risk

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.


Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Atopic Diseases Significantly Raise the Risk of Post-Surgical Complications

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Novo Nordisk has terminated the 1-year follow-up for the evoke and evoke+ trials after no significant reduction was indicated in either.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

The panel discusses how clinicians assess progression in IgA nephropathy and the importance of recognizing high-risk patients early. They emphasize that proteinuria is a central prognostic marker, and that achieving sustained reduction is critical. However, they note that ongoing eGFR decline, even when proteinuria appears improved, signals continued immune-mediated injury and should prompt re-evaluation. The group then addresses diagnostic challenges, including the fact that many patients first present after significant kidney damage has already occurred. To improve early detection, they support lowering the biopsy threshold to persistent proteinuria around 0.5 g/day, particularly when accompanied by hematuria. Increased awareness among primary care clinicians is highlighted as essential for earlier referral. Finally, the discussion includes the role of the RaDaR Registry, which collects long-term real-world data to help identify progression patterns and refine risk stratification. Overall, the segment underscores the need for early diagnosis and vigilant monitoring.

Video Series

RaDaR Insights on Proteinuria, eGFR Decline, and Diagnostic Challenges in IgAN

In this segment, the panelists discuss IgA Nephropathy, a glomerular disease primarily affecting young adults in their 20s and 30s. The condition has a slight predilection for males and Southeast Asians. Patients typically present asymptomatically with blood or protein in urine, or with gross hematuria following a respiratory tract infection. Less commonly, patients may develop severe nephrotic syndrome.
Clinicians are most concerned with proteinuria and kidney function. Patients with proteinuria exceeding 0.5 grams are considered at risk for disease progression. The panel emphasizes that diagnoses often occur too late, with patients already having lost nearly half their kidney function. This is particularly critical because these young patients have decades ahead of them, and even small annual kidney function losses can lead to end-stage kidney disease, potentially requiring dialysis. The early detection and monitoring of these patients are crucial for preserving long-term kidney health.


Clinical and Laboratory Findings Suggestive of IgA Nephropathy (IgAN)

Joseph Gatti, DMSc, MPAS, MBA, PA-C, is the founder of the Clinic for Dermatology & Wellness, LLC, and Pure Medspa, LLC. 

This interview at SDPA highlights Gatti's views on the impact of technology on radiology, pathology, and dermatology.

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.


Chronic Kidney Disease

Bariatric Surgery Type Impacts Survival for Older Patients with ESKD

Jason Hawkes, MD, MS, outlines key factors influencing the selection between biologics, oral small molecules, and traditional systemic therapies in CSU management.

Latest News

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up